BT 111
Alternative Names: BT-111Latest Information Update: 29 May 2024
At a glance
- Originator Landos Biopharma
- Class Anti-inflammatories; Antihypercalcaemics; Hepatoprotectants; Small molecules
- Mechanism of Action Inflammation mediator inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-alcoholic steatohepatitis; Type 1 diabetes mellitus
Most Recent Events
- 23 May 2024 Landos Biopharma has been acquired by AbbVie
- 28 Dec 2023 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA
- 28 Dec 2023 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in USA